StageZero Life Sciences Ltd.
SZLSFOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$630018
P/E Ratio—
52W High$0.03109
52W Low$0.0005
StageZero Life Sciences Ltd. (SZLSF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SZLSF · earnings · updated Jun 15, 2026
Latest Earnings
Q4 FY2024Report Date: Dec 16, 2024EPS Actual
-$0.00
Revenue
$0.00B
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Dec 16, 2024
After Market Close
SZLSF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 15, 2026 | — | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 19, 2026 | — | — | — | — | $0.00B | — |
| ◌ Q4 FY2025 | Dec 29, 2025 | — | — | — | — | $0.00B | — |
| ◌ Q3 FY2025 | Aug 28, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 16, 2025 | — | — | — | — | — | — |
| — Q4 FY2024 | Dec 16, 2024 | — | -$0.00 | — | $0.00B | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q2 FY2024 | May 15, 2024 | — | -$0.00 | — | $0.00B | — | — |
Q2 FY2026
Jun 15, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 19, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Dec 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 28, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 16, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 16, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Sep 30, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
May 15, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2024 | Dec 16, 2024 | — | $0.00 | $0.00 | +0.00% |
| — Q3 FY2024 | Sep 30, 2024 | — | $0.04 | $0.04 | +10.45% |
| — Q2 FY2024 | May 15, 2024 | — | $0.01 | $0.04 | +212.50% |
| — Q4 FY2023 | Nov 14, 2023 | — | $0.03 | $0.03 | +0.00% |
| — Q3 FY2023 | Aug 14, 2023 | — | $0.05 | $0.05 | +0.00% |
| — Q1 FY2023 | Mar 31, 2023 | — | $0.08 | $0.07 | -15.79% |
Q4 FY2024+0.00%
Report Date
Dec 16, 2024
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q3 FY2024+10.45%
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q2 FY2024+212.50%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.04
Q4 FY2023+0.00%
Report Date
Nov 14, 2023
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q3 FY2023+0.00%
Report Date
Aug 14, 2023
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.05
Q1 FY2023-15.79%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$0.08
Price After
$0.07
Beat Rate0 / 6 quarters
Largest Move+212.50% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SZLSF ends December
StageZero Life Sciences Ltd. (SZLSF) most recently reported earnings on December 16, 2024 for Q4 FY2024, posting EPS of $-0.00 (in line with the analyst consensus of —). The next SZLSF earnings date is expected around September 2, 2026.
Each quarter, investors track SZLSF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SZLSF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SZLSF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SZLSF earnings · 4 questionsStageZero Life Sciences Ltd.'s next earnings report is expected around September 2, 2026. SZLSF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SZLSF historically reports after market close (AMC).
SZLSF earnings datewhen is SZLSF earningsSZLSF next earnings datewhen does SZLSF report earningsSZLSF earnings calendar
▸ Source: FMP · StageZero Life Sciences Ltd. SEC filings · US GAAP · StageZero Life Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026